Price
Target price
€17.07
€17.07
-2.070%
-0.355
-2.070%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Syndax Pharmaceuticals Inc Stock
We can see a decrease in the price for Syndax Pharmaceuticals Inc. Compared to yesterday it has lost -€0.355 (-2.070%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Syndax Pharmaceuticals Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Syndax Pharmaceuticals Inc in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Syndax Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | -2.070% | -3.314% | -13.983% | 26.444% | -4.637% | -0.175% | 42.250% |
| Pacira Pharmaceuticals | 0.500% | -5.714% | -10.811% | -5.714% | -8.333% | -40.361% | -58.403% |
| Corcept Therapeutics Inc. | -1.090% | 2.335% | 27.906% | 65.117% | 48.070% | 259.043% | 456.319% |
| Supernus Pharmaceuticals | -0.480% | 1.970% | -1.429% | 15.642% | -3.721% | 48.921% | 99.038% |
News
Syndax Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Syndax Pharmaceuticals, Inc.? Here are five stocks we like better.
- Syndax’s Q2 revenue rose 92% year over year to $72.8 million, driven by Revuforj revenue of $54.7
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push
Key Points
- Interested in Syndax Pharmaceuticals, Inc.? Here are five stocks we like better.
- Syndax Pharmaceuticals is broadening its growth plan beyond Revuforj and Niktimvo, highlighting new
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
DAFNA Capital Management reported selling 222,847 shares of Syndax Pharmaceuticals (NASDAQ:SNDX) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.89 million based on
